Capecitabine is an antifolate anticancer chemotherapeutic that acts as a prodrug of 5-fluorouracil (5-FU), a fluoropyrimidine carbamate that inhibits thymidylate synthase. Capecitabine is converted to 5-FU by thymidine phosphorylase in vivo. Capecitabine displays varying efficacy in the treatment of colorectal, metastatic breast, prostate, ovarian, and pancreatic cancers.
| Cas No. | 154361-50-9 |
|---|---|
| Purity | ≥98% |
| Formula | C15H22FN3O6 |
| Formula Wt. | 359.35 |
| Chemical Name | pentyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate |
| IUPAC Name | pentylN-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate |
| Melting Point | 110-121°C |
| Appearance | White to off white powder |
| Store Temp | 4°C |
|---|---|
| Ship Temp | Ambient |
| Info Sheet | C0162 Info Sheet PDF |
|---|
Wilson PM, Fazzone W, LaBonte MJ, et al. Novel opportunities for thymidylate metabolism as a therapeutic target. Mol Cancer Ther. 2008 Sep;7(9):3029-37. PMID: 18790783.
Walko CM, Lindley C. Capecitabine: a review. Clin Ther. 2005 Jan;27(1):23-44. PMID: 15763604.
Ishikawa T, Utoh M, Sawada N, et al. Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol. 1998 Apr 1;55(7):1091-7. PMID: 9605432.
